<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292912</url>
  </required_header>
  <id_info>
    <org_study_id>212669</org_study_id>
    <nct_id>NCT04292912</nct_id>
  </id_info>
  <brief_title>Study 212669: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema</brief_title>
  <official_title>Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 After 28 Day Repeat Oral Administration to Adults With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, single arm, 28-day treatment in participants with DME.&#xD;
      The study will be composed of 3 periods for all participants: Screening, 28-day Treatment&#xD;
      period, and Follow-up visit (approximately 28 days after the final dose).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2020</start_date>
  <completion_date type="Anticipated">December 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a multi-center, open-label, single arm study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with abnormal ophthalmic examination findings</measure>
    <time_frame>At Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal refraction and visual acuity</measure>
    <time_frame>At Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal physical examination findings</measure>
    <time_frame>At Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in laboratory parameters, vital signs, and 12-lead electrocardiogram (ECG) findings</measure>
    <time_frame>At Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>At Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from Baseline in center subfield retinal thickness as measured by Spectral-Domain Optical Coherence Tomography (SD-OCT)</measure>
    <time_frame>Baseline and up to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of GSK2798745</measure>
    <time_frame>Day 7 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of major metabolite GSK3526876</measure>
    <time_frame>Day 7 and Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Participants receiving GSK2798745</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2798745</intervention_name>
    <description>GSK2798745 will be administered.</description>
    <arm_group_label>Participants receiving GSK2798745</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 to 75 years of age inclusive, at the time of signing the informed consent.&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus (type 1 or type 2).&#xD;
&#xD;
          -  Confirmation of DME with center involvement in at least one eye, including those with&#xD;
             focal or diffuse DME as determined by Investigator-determined fluorescein angiography.&#xD;
&#xD;
          -  Retinal thickening (diabetic macular edema) involving the center of the fovea in the&#xD;
             study eye as defined by Investigator-determined SD-OCT central subfield thickness&#xD;
             greater than (&gt;)340 microns for Heidelberg Spectralis or &gt;320 for Zeiss Cirrus; if&#xD;
             both eyes are eligible, the eye with the greater OCT center subfield score is selected&#xD;
             as the study eye if all other criteria are met. SD-OCT assessments for individual&#xD;
             patients must be taken with the same machine throughout the duration of the study.&#xD;
&#xD;
          -  Early Treatment Diabetic Retinopathy Study (ETDRS)-Best Corrected Visual Acuity (BCVA)&#xD;
             letter score of 80 letter or worse (Snellen equivalent: equivalent to 20/25) or worse&#xD;
             in the study eye. The non-study fellow eye should equivalent or better at Baseline,&#xD;
             pre-dose.&#xD;
&#xD;
          -  Safe to withhold treatment of the study eye with laser photocoagulation, intravitreal&#xD;
             steroid injection, or intravitreal vascular endothelial growth factor (VEGF) inhibitor&#xD;
             for the duration of the study.&#xD;
&#xD;
          -  Body weight greater than equal to (&gt;=) 50 kilograms (kg) and Body mass index (BMI)&#xD;
             within the range 18 to 40kg per square meter (inclusive) at screening.&#xD;
&#xD;
          -  Male participants will be eligible to participate if they agree to the following first&#xD;
             dose of study treatment until the follow-up visit: Refrain from donating sperm, plus&#xD;
             either be abstinent from heterosexual or homosexual intercourse as their preferred and&#xD;
             usual lifestyle (abstinent on a long term and persistent basis) and agree to remain&#xD;
             abstinent or Must agree to use contraception/barrier as detailed below: 1. Agree to&#xD;
             use a male condom and female partner to use an additional highly effective&#xD;
             contraceptive method with a failure rate of less than (&lt;)1 percent (%) per year, 2.&#xD;
             Should also be advised of the benefit for a female partner to use a highly effective&#xD;
             method of contraception as a condom may break or leak when having sexual intercourse&#xD;
             with a woman of childbearing potential who is not currently pregnant.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not of childbearing&#xD;
             potential.&#xD;
&#xD;
          -  Contraceptive use by men or women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          -  Participant is willing and able to return for all study visits and to comply with all&#xD;
             protocol requirements and procedures.&#xD;
&#xD;
          -  Participants capable of giving signed informed consent which includes compliance with&#xD;
             the requirements and restrictions listed in the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Additional eye disease in the study eye that in the opinion of the Investigator could&#xD;
             compromise assessment of SD-OCT, BCVA or imaging of the posterior pole by Fundus&#xD;
             Photography (FP), fluorescein angiography, or is likely to require intervention during&#xD;
             the study ( for example [e.g.], cataract, glaucoma with documented visual field loss,&#xD;
             ischemic optic neuropathy, retinitis pigmentosa).&#xD;
&#xD;
          -  History of choroidal neovascularization in the study eye, or current choroidal&#xD;
             neovascularization in the fellow eye requiring treatment.&#xD;
&#xD;
          -  Active Proliferative diabetic retinopathy (PDR) in the study eye or untreated active&#xD;
             PDR in the fellow eye.&#xD;
&#xD;
          -  Ischemic maculopathy on fluorescein angiography defined as a total area of capillary&#xD;
             loss greater that 2-disc areas (&gt;5millimeter square [mm^2]) within the ETDRA macular&#xD;
             grid or a foveal avascular zone greatest linear diameter of &gt;1000 microns.&#xD;
&#xD;
          -  Intraocular surgery or laser photocoagulation in the study eye within 90 day of dosing&#xD;
             which might compromise assessment of SD-OCT, BCVA or imaging of the posterior pole by&#xD;
             FP, fluorescein angiography. Allowed in fellow eye.&#xD;
&#xD;
          -  Use of intravitreal ranibizumab,or bevacizumab within 42 days (6 weeks), or&#xD;
             aflibercept within 56 days (8 weeks) of dosing in the study eye. Allowed in fellow&#xD;
             eye.&#xD;
&#xD;
          -  Use of intraocular steroids in the study eye within 180 days of dosing. Allowed in&#xD;
             fellow eye.&#xD;
&#xD;
          -  Use of or expected need for intravitreal or intraocular treatment in the study eye&#xD;
             during course of the study. Allowed in fellow eye.&#xD;
&#xD;
          -  Use of any systemically administered anti-angiogenic agent (e.g., bevacizumab,&#xD;
             sunitinib, cetuximab, sorafenib, pazopanib), approved or investigational, within 6&#xD;
             months of dosing.&#xD;
&#xD;
          -  Evidence of vitreomacular traction as determined by the Investigator.&#xD;
&#xD;
          -  Uncontrolled intraocular pressure &gt;22 millimeters of mercury in the study eye despite&#xD;
             treatment with glaucoma medication.&#xD;
&#xD;
          -  Within 6 months prior to the Screening Visit, use of medications known to be toxic to&#xD;
             the retina, lens or optic nerve (e.g., desferoximine, chloroquine/hydrochloroquine,&#xD;
             chlorpromazine, phenothiazines, tamoxifen, interferons and ethambutol) or are&#xD;
             implicated in the development of macular edema (e.g. thiazolidinesdiones, fingolimod).&#xD;
&#xD;
          -  Uncontrolled diabetes as indicated by glycated hemoglobin (HbA1c) &gt;10% at Screening.&#xD;
&#xD;
          -  Active ulcer disease or gastrointestinal bleeding at the time of Screening (positive&#xD;
             Fecal Occult Blood Test (FOBT) at screening).&#xD;
&#xD;
          -  Current or chronic history of liver disease or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  History of stroke or seizure disorder within 1 year of Screening.&#xD;
&#xD;
          -  Participant who, in the Investigator's opinion, poses a significant suicide risk.&#xD;
             Evidence of serious suicide risk may include any history of suicidal behavior and/or&#xD;
             any evidence of suicidal ideation on any questionnaires e.g., Type 4 or 5 on the&#xD;
             Columbia Suicidality Severity Rating Scale (CSSRS) in the last 6 months (assessed at&#xD;
             Screening).&#xD;
&#xD;
          -  History or current evidence of any serious or clinically significant cardiac,&#xD;
             gastrointestinal, renal, endocrine, neurologic, hematologic, infectious or other&#xD;
             condition that is uncontrolled on permitted therapies or that would, in the opinion of&#xD;
             the Investigator or the Medical Monitor, make the participant unsuitable for inclusion&#xD;
             in this study.&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &gt;1.5 times upper limit of normal (ULN).&#xD;
&#xD;
          -  Bilirubin &gt;1.5 times ULN (isolated bilirubin &gt;1.5 times ULN is acceptable if bilirubin&#xD;
             is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Evidence of abnormal clinical laboratory finding prior to enrollment that, in the&#xD;
             opinion of the Investigator, makes the participant unsuitable for the study.&#xD;
&#xD;
          -  Corrected (QTc) interval &gt;450 milliseconds (msec) or QTc &gt;480 msec in participants&#xD;
             with bundle branch block.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5&#xD;
             half-lives (whichever is longer) prior to the first dose of study drug, unless in the&#xD;
             opinion of the Investigator and GlaxoSmithKline (GSK) Medical Monitor the medication&#xD;
             will not interfere with the study procedures or compromise participant safety.&#xD;
&#xD;
          -  Use of a listed precluded medication, including strong inhibitors or inducers of&#xD;
             cytochrome P450 (CYP) 3A or p-glycoprotein, within the restricted timeframe relative&#xD;
             to the first dose of the study treatment.&#xD;
&#xD;
          -  Participation in the study would result in loss of blood or blood products in excess&#xD;
             of 500 milliliter within 3 months from screening.&#xD;
&#xD;
          -  Exposure to more than 4 new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Current enrollment, or past participation within the last 60 days, of any clinical&#xD;
             study involving an investigational study intervention, or any other type of medical&#xD;
             research, before signing of consent for this study.&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV) antibody test.&#xD;
&#xD;
          -  Presence of Hepatitis B surface antigen (HBsAg) at screening or within 3 months prior&#xD;
             to first dose of study intervention.&#xD;
&#xD;
          -  Positive Hepatitis C antibody test result at screening or within 3 months prior to&#xD;
             starting study intervention.&#xD;
&#xD;
          -  Positive Hepatitis C ribonucleic acid (RNA) test result at screening or within 3&#xD;
             months prior to first dose of study intervention.&#xD;
&#xD;
          -  Cardiac troponin at screening &gt; ULN for the assay.&#xD;
&#xD;
          -  Sensitivity to any of the study interventions, or components thereof, or drug or other&#xD;
             allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates&#xD;
             participation in the study.&#xD;
&#xD;
          -  Regular substance abuse including drug and/or alcohol consumption within 6 months&#xD;
             prior to the study. Alcohol consumption is defined as: An average weekly intake of &gt;&#xD;
             14 units. One unit is equivalent to 8 gram of alcohol: a half-pint (equivalent to 240&#xD;
             milliliters[mL]) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kent Small</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>John Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joel Pearlman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Monique Barbour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>John Randolph</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shirley</city>
        <state>New York</state>
        <zip>11967</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pamela Weber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Devine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Castle Hill</city>
        <state>New South Wales</state>
        <zip>2154</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Angela Jennings</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald Paul Mitchell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sepehr Shakib</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ben Snyder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic macular edema</keyword>
  <keyword>GSK2798745</keyword>
  <keyword>Refraction</keyword>
  <keyword>Visual acuity.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

